Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for…

By J. Dipersio, I. Micallef, P. Stiff, B. Bolwell, R. Maziarz, E. Jacobsen, A. Nademanee, J. McCarty, G. Bridger, G. Calandra. Journal of Clinical Oncology, 2009

639 citations recorded by the source corpus.

Subfields: Hematology, Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/0fde7ca38b6cf5cb87546ef301d1ee1894a3d232

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Thomas J. Smith
2. Kari Bohlke
3. G. Lyman
4. K. Carson
5. J. Crawford
6. Scott J. Cross
7. J. Goldberg
8. N. Leighl

Citations in the corpus

• Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. (2015, methodology): “The combination of a G-CSF and plerixafor has been evaluated in two phase III clinical trials.(47,48) Compared with a G-CSF alone, the combination of a G-CSF and plerixafor increased the number of patients who reached optimal CD34 cell targets within a specified number of apheresis days.”